SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following its announcement of a record date for a digital token initiative, drawing significant community discussion around its venture into crypto. This attention is amplified by escalating geopolitical rhetoric, including commentary on Greenland and new tariff threats, which is heavily influencing market sentiment and broader economic concerns. The stock continues to be a focal point for politically charged narratives, with both enthusiastic supporters and market participants expressing strong, polarized views.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending due to its recent announcement to acquire a luxury wine authentication and trading business, diversifying its offerings beyond caviar. However, a public offering at $7.00 per unit has led to significant price volatility and a sharp decline, sparking strong community debate about whether the move signals a legitimate long-term strategy or a "pump and dump" scenario. Investors are actively discussing the immediate impact of the offering and the company's valuation amidst these developments.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its oral drug, soquelitinib, in treating moderate to severe atopic dermatitis, particularly in patients resistant to other therapies. The outstanding efficacy and safety profile from this early data are generating significant community excitement, with many anticipating blockbuster potential and a paradigm shift for inflammation and immunology, while some caution about the trial's small size and potential for a future stock offering.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant, a move widely seen as powerful validation for the platform technology beyond its initial COVID application. The community is actively debating whether this partnership signals NVAX's evolution into a royalty-generating company and if high short interest will trigger a substantial upward move, despite some expressing frustration over the immediate market reaction amidst a broader downturn.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant traction following key innovation awards and its confirmed partnership with Celestial AI, recently acquired by Marvell, igniting optimism for upcoming major customer announcements. The community is actively discussing strong market momentum and a potential gamma squeeze, highlighting the company's unique optical interposer technology as a critical enabler for AI and data center infrastructure.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a major talking point as geopolitical tensions escalate over the US's pursuit of Greenland and potential tariffs, prompting a Danish pension fund to divest from US Treasuries citing credit risk concerns. The community remains sharply divided, with some fearing broader international divestment and higher yields while others anticipate eventual rate cuts amid a slowing economy and increased Fed intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate.</li><li>Patients treated with Temferon in the study had a median overall survival remains at 17 months, consistent with prior findings.</li><li>A patient in the study also reached three years of survival following Temferon administration, the company said.</li></ul>Shares of Genenta Science (GNTA) soared 10% in the pre-market session on Monday after the company announced long-term survival trends from the study of its cell therapy in the treatment of some newly diagnosed glioblastoma multiforme (GBM) patients.Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate. Genenta is studying Temferon, an experimental cell therapy, in the patient population.<h2 class="st-heading-2">What Does The Study Show?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193229/0/en/Genenta-Reports-Long-Term-Survival-Trends-and-Immune-Findings-in-Brain-Tumor-GBM-Trial.html">said</a> that 25 patients have been treated with Temferon as of November 21, and 44% of patients have reached 18-month survival. This marks an increase from April, when the company had announced that 38% of patients had reached 18-month survival.Median overall survival remains at 17 months, consistent with prior findings, while the two-year survival rate continues to be 29%, the company said, while adding that median overall survival on standards of care is typically 13-15 months with a two-year survival rate of about 14%.A patient in the study also reached three years of survival following Temferon administration, the company said. Overall, the study also provided early immune observations on Temferon’s behavior within the tumor microenvironment, it added. The observations must now be confirmed in larger, controlled studies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GNTA jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:584/55;" src="data:image/png;base64,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" width="584" height="55"><figcaption>GNTA’s Sentiment Meter and Message Volume as of 6:15 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/GNTA">GNTA stock</a> is down by 61% this year and by about 65% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/deere-q4-earnings-seen-under-pressure-amid-weak-farmer-sentiment/cL5bdq0REfH">Deere Q4 Earnings Seen Under Pressure Amid Weak Farmer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Genenta Science logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.

Equity

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.


<ul class="summary-bullets"><li>Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.</li><li>The partnership aims to advance an off-the-shelf LVV Plasmid DNA platform to improve gene therapy production.</li><li>Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies.</li></ul>Genenta Science (GNTA) stock is set to hit an all-time high on Friday after the company announced that it has joined forces with biotech manufacturing organization ANEMOCYTE to develop tools for gene and cell therapy.&nbsp;At&nbsp;the time of writing&nbsp;<a href="https://stocktwits.com/symbol/GNTA">Genenta Science stock</a> traded over 300% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;The collaboration centers on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform to boost the production of high-quality genetic materials used in advanced therapies.<h2 class="st-heading-2">Expanded Partnership</h2>The new strategic agreement strengthens an already productive relationship between the two firms, previously focused on Plasmid DNA manufacturing.&nbsp;The companies intend to combine Genenta’s experience with LVV Plasmid DNA technology, originally derived from the research of co-founder Professor Luigi Naldini, with ANEMOCYTE’s production capabilities to deliver dependable materials for research and clinical applications.What Is Genenta Science Known For?&nbsp;Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies that harness hematopoietic stem cells to fight tumor cancers. Its lead candidate, Temferon, is engineered to deliver immune-activating payloads directly within the tumor microenvironment through modified bone marrow-derived cells, aiming for a precise and lasting anti-cancer effect.<blockquote>“By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry.”-Pierluigi Paracchi, CEO, Genenta Science.</blockquote>Genenta Science's stock has lost over 25% in 2025 and over 39% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-apple-meta-lead-private-funding-for-trump-s-white-house-ballroom/cLGJQyRR3s4">Alphabet, Apple, Meta Lead Private Funding For Trump’s ‘Big, Beautiful’ $250M White House Ballroom Project, Donor List Reveals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A piece of a plasmid model is stained at Biontech's Goerzhausen I site.

GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

GNTA
Genenta Science SpA - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest GNTA News

GNTAGenenta Science SpA - ADR